We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO Downgrades Rating of FDA’s Action Plans for Postmarket Monitoring
GAO Downgrades Rating of FDA’s Action Plans for Postmarket Monitoring
In its latest biennial report to Congress on high-risk government programs, the GAO downgraded its rating of the FDA’s action plans, saying CDER, CBER and CDRH’s long-term strategies lack adequate details and performance measures.